Abstract
Background
The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio has been shown to be a predictor of cardiovascular (CV) outcomes in the general population. The aim of this study was to determine whether the TG/HDL-C ratio is a predictor of CV events and all-cause mortality in maintenance hemodialysis (MHD) patients.
Methods
We performed a retrospective, observational cohort study in which we enrolled 193 MHD patients from a single center in Japan who had been followed up for a median of 3.9 years. The outcomes were the occurrence of a CV event and all-cause mortality during the follow-up period. Baseline TG/HDL-C ratios were investigated for associations with outcomes by using Cox regression models adjusted for demographic parameters.
Results
Overall, 88 of the subjects experienced a CV event, and 32 patients had died, of whom 4 died due to CV events. Patients with higher TG/HDL-C levels (tertile 3) had a higher incidence of CV events (adjusted hazard ratio [HR] 1.82, 95 % confidence interval [CI] 1.01–3.35) and higher all-cause mortality (adjusted HR 6.13, 95 % CI 2.13–20.22) than the patients in tertile 1. Kaplan–Meier analyses by the log-rank test showed that the TG/HDL-C ratio had significant predictive power for detecting a CV event.
Conclusions
The TG/HDL-C ratio is a reliable and easily accessible marker for predicting CV events and mortality in MHD patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shinjuku Ishikawa Clinic, Department of Nephrology, Tokyo, Japan
2 Tokyo Women’s Medical University, Department of Medicine, Kidney Center, Tokyo, Japan (GRID:grid.410818.4) (ISNI:0000000107206587)




